U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT07530770) titled 'Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis' on Dec. 07, 2025.
Brief Summary: An open-label study will evaluate effects of Benralizumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis
Study Start Date: Sept. 01, 2025
Study Type: OBSERVATIONAL
Condition:
Allergic Bronchopulmonary Aspergillosis
Severe Asthma
ABPA
Intervention:
DRUG: Fasenra
30 Mg/mL Subcutaneous Solution
Recruitment Status: RECRUITING
Sponsor: Qianfoshan Hospital
Information provided by (Responsible Party): Qian Qi, Qianfoshan Hospital
Disclaimer: Curated by HT Syndication....